Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    Recruiting Studies | Interventional Studies | Gastric Cancer | nova scotia | Canada

A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (INTEGRATEIIa)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02773524
Recruitment Status : Recruiting
First Posted : May 16, 2016
Last Update Posted : May 7, 2021
Sponsor:
Collaborators:
Canadian Cancer Trials Group
Academic and Community Cancer Research United
National Health and Medical Research Council, Australia
Information provided by (Responsible Party):
Australasian Gastro-Intestinal Trials Group

Tracking Information
First Submitted Date  ICMJE May 4, 2016
First Posted Date  ICMJE May 16, 2016
Last Update Posted Date May 7, 2021
Actual Study Start Date  ICMJE November 2016
Estimated Primary Completion Date June 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 21, 2018)
Overall Survival [ Time Frame: From time of patient randomisation until date last known alive (up to 12 months following end of treatment). ]
The interval from the date of randomisation to date of death from any cause, or the date last known alive.
Original Primary Outcome Measures  ICMJE
 (submitted: May 12, 2016)
Overall Survival [ Time Frame: up to at least 36 months ]
Patients followed until 300 deaths occur e.g. over a 24 month recruitment period plus an additional follow-up period of at least 12 months.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 21, 2018)
  • Progression Free Survival [ Time Frame: From time of patient randomisation until first evidence of disease progression or death (up to 12 months following randomisation). ]
    The interval from the date of randomisation to the date of first evidence of disease progression or death, whichever occurs first.
  • Objective Tumour Response Rate [ Time Frame: From time of patient randomisation until evidence of complete or partial response (up to 12 months following randomisation). ]
    The OTRR will be calculated by summing the number of participants in a given arm that are assessed as having a complete or partial response (as per RECIST criteria), and dividing this by the total number of participants in the corresponding arm of the analysis set.
  • Evaluation of health states experienced by participants [ Time Frame: From time of commencement of treatment until first evidence of disease progression (up to 12 months following commencement of treatment). ]
    Questionnaire used to assess quality of life
  • Rates of Adverse Events [ Time Frame: From time dose of study treatment until 30 days after last dose of study treatment ]
    A descriptive analysis of the adverse events (AE) data will be prepared for participants in the safety population. The number and percentage of participants who experience AEs will be tabulated according to CTCAE term/category, grade, and seriousness.
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures
 (submitted: May 4, 2021)
  • Identification of tumour markers to that predict treatment outcomes for AGOC [ Time Frame: Up to 24 months following close of recruitment. ]
    Biomarker assessment, CTC DNA assessment to predict whether treatment for AGOC is efficacious
  • Evaluation of regorafenib Maximum Plasma Concentration [Cmax] between Asia and Rest of World cohorts. [ Time Frame: Up to 24 months following close of recruitment. ]
    Evaluation of regorafenib Maximum Plasma Concentration [Cmax] in patients from either Asia or ROW to assess whether genetic factors aide/hinder metabolic rate of consumption of regorafenib
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer
Official Title  ICMJE A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
Brief Summary A randomised phase III, double-blind, placebo-controlled trial with 2:1 (regorafenib : placebo)
Detailed Description

Purpose:

The purpose of this Phase III study is to determine if regorafenib improves overall survival in patients with Advanced Gastro-Oesophageal Carcinoma.

Who is it for:

You may be eligible to join this study if you are aged 18 years or above and have been diagnosed with advanced (metastatic or locally recurrent) Gastro-Oesophageal Carcinoma which has not responded to a minimum of 2 lines of prior anti-cancer therapy.

Trial Details:

Participants will be randomly (by chance) allocated to one of two groups: regorafenib or placebo in 2:1 ratio respectively and will not be aware of their group allocation. Regorafenib or matching placebo will be self-administered by participants orally once daily on days 1-21 of each 28 days cycle. Treatment will continue until disease progression or prohibitive toxicity. Participants will be followed up every 2-4 weeks in order to evaluate their progress on the study.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Gastro-Oesophageal Cancer
Intervention  ICMJE
  • Drug: Regorafenib
    Regorafenib is the experimental intervention in this study. Regorafenib will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
    Other Name: Stivarga
  • Other: Placebo
    Placebo (matching in appearance to regorafenib) made of microcrystalline cellulose, will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
Study Arms  ICMJE
  • Experimental: Regorafenib
    Regorafenib 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
    Intervention: Drug: Regorafenib
  • Placebo Comparator: Placebo
    Placebo 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
    Intervention: Other: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 12, 2016)
350
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2022
Estimated Primary Completion Date June 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

  1. Adults (18 years or over) with metastatic or locally recurrent gastro-oesophageal cancer which:

    1. has arisen in any primary gastro-oesophageal site (oesophago-gastric junction (GOJ) or stomach); and
    2. is of adenocarcinoma or undifferentiated carcinoma histology , and
    3. is evaluable according to Response Evaluation Criteria in Solid Tumours (RECIST Version 1.1) by computed tomography (CT) scan performed within 21 days prior to randomisation. A lesion in a previously irradiated area is eligible to be considered as measurable disease as long as there is objective evidence of progression of the lesion prior to study enrolment; and
    4. has failed or been intolerant to a minimum of 2 lines of prior anti-cancer therapy for recurrent/metastatic disease which must have included at least one platinum agent and one fluoropyrimidine analogue.

      Note: Neoadjuvant or adjuvant chemotherapy or chemoradiotherapy will be considered as first line treatment where people have relapsed or progressed within 6 months of completing treatment; Radiosensitising chemotherapy given solely for this purpose concurrent with palliative radiation will not be considered as a line of treatment. Ramucirumab monotherapy, or immunotherapy with a checkpoint inhibitor, will be considered a line of treatment.

    5. HER2-positive participants must have received trastuzumab.
  2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  3. Ability to swallow oral medication.
  4. Adequate bone marrow function (Platelets ≥100x109/L; Absolute Neutrophil Count (ANC) ≥1.5x109/L and Haemoglobin ≥ 9.0g/dL).
  5. Adequate renal function (Creatinine clearance >50 ml/min) based on either the Cockcroft-Gault formula (Appendix 2), 24-hour urine or Glomerular Filtration Rate (GFR) scan; and serum creatinine ≤1.5 x Upper Limit of Normal (ULN).
  6. Adequate liver function (Serum total bilirubin ≤1.5 x ULN, and INR ≤ 1.5 x ULN, and Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP) ≤2.5 x ULN (≤ 5 x ULN for participants with liver metastases)). Participants being treated with an anti-coagulant, such as warfarin or heparin, will be allowed to participate provided that no prior evidence of an underlying abnormality in these parameters exists.
  7. Adequate cardiac function (Left Ventricular Ejection Fraction (LVEF) ≥ 50% or above the lower limit of normal (LLN) for the Institution (whichever is lower). Cardiac function should be assessed within 3 months prior to randomisation, but after completion of any anthracycline-containing chemotherapy.
  8. Willing and able to comply with all study requirements, including treatment, timing, and/or nature of required assessments and follow-up.
  9. Study treatment both planned and able to start within 7 days after randomisation (note: subjects randomised on a Friday should commence treatment no earlier than the following Monday).
  10. Signed, written informed consent.

Exclusion Criteria

  1. Known allergy to the investigational product drug class or excipients in the regorafenib.
  2. Poorly-controlled hypertension (systolic blood pressure >140mmHg or diastolic pressure> 90mmHg despite optimal medical management).
  3. Participants with known, uncontrolled malabsorption syndromes.
  4. Any prior anti-VEGF targeted therapy using small molecule VEGF TKIs (e.g. apatinib). Prior anti-VEGF targeted monoclonal antibody therapies (e.g. bevacizumab and ramucirumab) are permitted.
  5. Treatment with any previous drug therapy within 2 weeks prior to first dose of study treatment. This includes any investigational therapy.
  6. Use of biological response modifiers, such as granulocyte colony stimulating factor (G-CSF), within 3 weeks prior to randomisation.
  7. Concurrent treatment with strong CYP3A4 inhibitors or inducers.
  8. Palliative radiotherapy, unless more than 14 days have elapsed between completion of radiation and the date of registration, and adverse events resulting from radiation have resolved to< Grade 2 according to CTCAE V4.03.
  9. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization.
  10. Arterial thrombotic or ischaemic events, such as cerebrovascular accident, within 6 months prior to randomization.
  11. Venous thrombotic events and pulmonary embolism within 3 months prior to randomization.
  12. Any haemorrhage or bleeding event ≥ Grade 3 according to CTCAE v4.03 within 4 weeks prior to randomization.
  13. Non-healing wound, ulcer, or bone fracture.
  14. Interstitial lung disease with ongoing signs and symptoms.
  15. Clinical hyperthyroidism or hypothyroidism. Note: non-clinically significant abnormal TFTs (abnormal TSH and abnormal T3 and/or abnormal T4) considered to be due to sick euthyroid syndrome is allowed.
  16. Persistent proteinuria of ≥ Grade 3 according to CTCAE v4.03 (equivalent to > 3.5g of protein over 24 hours, measured on either a random specimen or 24 hour collection).
  17. Uncontrolled metastatic disease to the central nervous system. To be eligible, CNS metastases should have been treated with surgery and/or radiotherapy and the patient should have been receiving a stable dose of steroids for at least 2 weeks prior to randomization, with no deterioration in neurological symptoms during this time.
  18. History of another malignancy within 2 years prior to randomization. Participants with the following are eligible for this study:

    1. curatively treated cervical carcinoma in situ,
    2. non-melanomatous carcinoma of the skin,
    3. superficial bladder tumours (T1a [Non-invasive tumour], and Tis[Carcinoma in situ]),
    4. treated thyroid papillary cancer
  19. Any significant active infection, including chronic active hepatitis B, hepatitis C, or HIV. Testing for these is not mandatory unless clinically indicated. Participants with known Hepatitis B/C infection will be allowed to participate providing evidence of viral suppression has been documented and the patient remains on appropriate anti-viral therapy.
  20. Serious medical or psychiatric condition(s) that might limit the ability of the patient to comply with the protocol.
  21. Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to randomization. Men must have been surgically sterilized or use a barrier method of contraception.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: INTEGRATE II Mailbox integrateii@ctc.usyd.edu.au
Listed Location Countries  ICMJE Canada,   Australia,   Japan,   Korea, Republic of,   New Zealand,   Taiwan,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02773524
Other Study ID Numbers  ICMJE AG0315OG
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Australasian Gastro-Intestinal Trials Group
Study Sponsor  ICMJE Australasian Gastro-Intestinal Trials Group
Collaborators  ICMJE
  • Canadian Cancer Trials Group
  • Academic and Community Cancer Research United
  • National Health and Medical Research Council, Australia
Investigators  ICMJE
Study Chair: Nick Pavlakis, Prof AGITG
PRS Account Australasian Gastro-Intestinal Trials Group
Verification Date May 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP